8-K: Denali Capital Acquisition Corp. Amends Merger Agreement with Semnur Pharmaceuticals Amid Nasdaq Delisting

Denali Capital Acquisition Corp. and Semnur Pharmaceuticals have amended their merger agreement to address Denali's delisting from Nasdaq and subsequent quotation on the OTC Markets, among other changes.

Summary

• Denali Capital Acquisition Corp. has amended its merger agreement with Semnur Pharmaceuticals and Denali Merger Sub Inc.
• The amendment addresses Denali's delisting from the Nasdaq Capital Market and its subsequent quotation on the OTC Markets Group, Inc.
• Denali is required to amend its organizational documents to extend the period for completing a business combination to December 11, 2025, or another mutually agreed date.
• The Outside Date for completing the merger has been extended to September 30, 2025, with a possible further extension if an Extension Amendment is in effect.
• Denali will file a definitive proxy statement/final prospectus with the SEC and mail it to shareholders to solicit proxies for the extraordinary general meeting to approve the Business Combination.
• The company will seek shareholder approval for matters including the Domestication and Plan of Domestication, the adoption and approval of the Merger Agreement, adoption of the Parent Certificate of Incorporation and the Parent Bylaws, election of the directors of Parent, the adoption and approval of the issuance of the Domesticated Parent Common Shares, the exchange of Company Options for Domesticated Parent Options, and approval to adjourn the Parent Special Meeting, if necessary.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the Nasdaq delisting and the need to amend the merger agreement and extend deadlines. While the company is taking steps to address these issues, they introduce uncertainty and potential risks.

Positives

• The amendment allows the merger process to continue despite Denali's delisting from Nasdaq.
• Extending the Outside Date provides more time to complete the merger.
• The company is taking steps to maintain the listing or quotation of its securities on the OTC Markets.

Negatives

• Denali's delisting from Nasdaq is a negative event.
• The need to extend the Outside Date suggests potential challenges in completing the merger within the original timeframe.

Risks

• The inability to consummate the Business Combination.
• Legal proceedings that may be instituted against the parties following the announcement of the Business Combination.
• The receipt of an unsolicited offer from another party for an alternative business transaction that could interfere with the Business Combination.
• The risk that the approval of the stockholders of Semnur or the shareholders of Denali for the potential transaction is not obtained.
• Failure to realize the anticipated benefits of the Business Combination.
• The risk that the Business Combination disrupts current plans and operations.
• The ability of the combined company to grow and manage growth profitably and retain its key employees.
• The amount of redemption requests made by Denalis shareholders.
• The inability to obtain or maintain the listing of the post-acquisition companys securities on Nasdaq or OTC Markets following the Business Combination.
• Costs related to the Business Combination.

Future Outlook

The company is focused on completing the Business Combination, obtaining shareholder approval, and maintaining the listing or quotation of its securities.

Industry Context

SPAC mergers are subject to regulatory scrutiny and market volatility, and delisting from major exchanges can impact investor confidence and access to capital.

Comparison to Industry Standards

• Many SPACs have faced challenges in completing mergers and maintaining listing requirements.
• The delisting from Nasdaq is similar to other SPACs that have failed to meet listing requirements due to low share prices or other factors.
• Extending the Outside Date is a common practice among SPACs facing delays in completing their business combinations.
• Comparable companies include other SPACs that have merged with pharmaceutical companies, such as the merger between Arya Sciences Acquisition Corp IV and Immatics Biotechnologies.

Stakeholder Impact

• Shareholders face uncertainty due to the Nasdaq delisting and potential delays in the merger.
• The company's ability to complete the merger and maintain its listing or quotation will impact investor confidence.
• Employees of both Denali and Semnur may experience uncertainty during the merger process.

Next Steps

• Denali will file a definitive proxy statement/final prospectus with the SEC.
• Denali will mail the proxy statement/final prospectus to shareholders.
• Denali will hold an extraordinary general meeting of shareholders to approve the Business Combination and related matters.
• Denali will seek to maintain the listing or quotation of its securities on the OTC Markets.

Key Dates

Keywords

Merger Agreement, Denali Capital Acquisition Corp., Semnur Pharmaceuticals, Business Combination, Nasdaq Delisting, OTC Markets, Amendment, Proxy Statement, Shareholder Approval, Extension Amendment